Technologies
PDF


WARF: P07312US

HPV-Positive Biomarkers for Cervical and Head and Neck Cancers


INVENTORS -

Paul Lambert, Michael Newton, Dohun Pyeon, Paul Ahlquist

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing methods of using HPV-positive biomarkers to determine if a person or animal has cervical or head and neck cancer, or if a person or animal is at risk of developing one of these cancers.
OVERVIEWHuman papillomaviruses (HPVs) are the most common sexually transmitted pathogens. These small DNA viruses are associated with almost all cervical cancers and 20 to 30 percent of head and neck cancers.

Cervical cancer is the second most common cancer in women worldwide.  It is a major cause of morbidity and mortality.  Head and neck cancer is the fourth most frequent cancer worldwide and the sixth most common cancer in the U.S.  The survival rate is less than 50 percent, and that statistic has not improved in decades.

Early diagnostic options, including the Pap smear and HPV DNA test, are available for cervical cancer.  However, no such test exists for head and neck cancer, which arises in the mucosal epithelia of the mouth/throat region.
THE INVENTIONUW-Madison researchers have identified three potential biomarkers that are specific for HPV-positive cancers in cervical and head and neck tumors: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3).  These biomarkers can be used to detect cervical or head and neck cancer.  TCAM1 and SYCP2 also can be used to detect precancerous lesions.

TCAM1, SYCP2 and STAG3 are testis-specific human genes.  The inventors have shown that mRNA from these genes is expressed in HPV-positive head and neck and cervical cancers but cannot be detected in normal somatic tissues or HPV-negative head and neck cancers.

Additionally, the TCAM1 protein likely is expressed on the cell surface, which would make it an accessible, easily-assayed biomarker for HPV-positive cells in cancers and precancerous lesions.  TCAM1 also may provide a useful target for therapies against HPV-positive cancers and precancerous lesions.
APPLICATIONS
  • Biomarkers for head and neck or cervical tumors, as well as precancerous lesions that may lead to head and neck or cervical cancer
  • Drug screening targets
  • Biomarkers for monitoring the effectiveness of cancer treatment
KEY BENEFITS
  • Provides specific biomarkers for HPV-positive cancers and precancerous lesions
  • Not expressed in normal somatic cells or HPV-negative cancers
  • TCAM1 likely is expressed on the cell surface, making it accessible and easily assayed
  • May be used to detect other HPV-positive cancers, including anal, penile, vaginal or vulva cancer
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Intellectual Property
Publications
  • Pyeon et al. 2007. Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus-Positive and Human Papillomavirus-Negative Head/Neck and Cervical Cancers. Cancer Res. 67, 4605-4619.
Contact Information
For current licensing status, please contact Mark Staudt at mstaudt@warf.org or 608-960-9845.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.